Company intelligence / Profile preview

Parse Biosciences

Seattle, Washington, United Statesparsebiosciences.com ↗

Ownership: Private
Employees: ~76
Development stage: Commercial

Overview

Parse Biosciences has commercialized its proprietary split-pool combinatorial barcoding technology for scalable single-cell RNA sequencing. Their products are widely adopted by over a thousand labs globally and have enabled discoveries in diverse fields such as oncology, immunology, neurology, and regenerative medicine. The company continues to expand its product portfolio with new applications like immune profiling and pooled CRISPR screens.

Industry: Non-Drug Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2024.

Beyond the preview

Go deeper on Parse Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parse Biosciences.

Explore the full profile